cagrilintide stacked with retatrutide + Dosing: Stack Protocol (2026) Cagrilintide and Retitutide | TikTok

Clinical Diabetes 41 , 467473 (2023)

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

Why Most GLP-1 Medicines Are Given by Injection GLP-1-based peptide medicines are injected because digestive enzymes rapidly break them down before oral absorption can occur, rendering conventional tablets or capsules ineffective

And none have been shown to produce meaningful weight loss when delivered through a patch